A Bull's Eye for Targeted Lung Cancer Therapy

See allHide authors and affiliations

Science  04 Jun 2004:
Vol. 304, Issue 5676, pp. 1458-1461
DOI: 10.1126/science.1099578

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


The tyrosine kinase inhibitor gefitinib has had mixed results in the treatment of lung cancer. The reason is now revealed in two papers published here ( Paez et al.) and elsewhere, which receive in-depth discussion in a Perspective by Minna et al. The two new studies show that tumors from a subset of lung cancer patients with an efficacious response to gefitinib carry mutations in the kinase domain of the EGF receptor. The new findings should enable early selection of those lung cancer patients most likely to respond well to gefitinib.